NCT06367153View on ClinicalTrials.gov

A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood

PHASE1CompletedINTERVENTIONAL
Enrollment

18

Participants

Timeline

Start Date

May 15, 2024

Primary Completion Date

August 20, 2024

Study Completion Date

August 20, 2024

Conditions
Healthy
Interventions
DRUG

BI 1569912

BI 1569912

DRUG

repaglinide

repaglinide

DRUG

midazolam

midazolam

DRUG

bupropion

bupropion

Trial Locations (1)

2650

SGS Life Science Services - Clinical Research, Edegem

Sponsors
All Listed Sponsors
lead

Boehringer Ingelheim

INDUSTRY

NCT06367153 - A Study in Healthy Men and Women to Test Whether BI 1569912 Influences the Amount of Repaglinide, Midazolam and Bupropion in the Blood | Biotech Hunter | Biotech Hunter